NASDAQ NMS - GLOBAL MARKET · JSPR
+5.73% · +$0.0396 · Vol 780.7K
Market closed · last close 4:00 PM ET · price as of 16:54:03 ET
Jasper Therapeutics Inc

Jasper Therapeutics Inc

Biotechnology
$0.7308
Card
Relationship Map

Veridion Score

BETALOW CONF · 4/6 factorsMethodology
Earnings absence reason unknown · Analyst data unavailable at compute time
JSPR
Jasper Therapeutics Inc
Fri Aug 21 · last completed session · Markets closed · resumes Mon 9:30 ET
AVOID

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

21/ 100
Veridion Score
AVOID · LOW confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 4/6 factors with data · Fri Aug 21 · last completed session · Markets closed · resumes Mon 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is JSPR moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading JSPR catalysts
About Jasper Therapeutics Inc
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed since
2021
Employees
22
Country
US

Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$0.6800
Day high
$0.7357
Day low
$0.6750
Previous close
$0.6912
52W high
$2.96
-75.31% from high
52W low
$0.3410
15% of range
Market cap
$23.8M
EPS
$-2.6800
Beta
1.96
Shares out
33.3M
Volume
780.7K
0.32× rel vol
Avg volume
2.5M
VWAP
$0.6999
Price history computed in-house
1W
-7.51%
1M
+6.16%
3M
-19.07%
1Y
-75.06%
YTD
-60.07%
SMA 50 $0.6240 · above
SMA 200 $1.14 · below
52W position 15%

JSPR overview

Veridion Score
21
Registered · 2026-08-21
4 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around JSPR.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading JSPR Form 4 filings
Public disclosures

Congress activity in JSPR

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for JSPR in the cached public ledger.

Federal contracts

JSPR contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for JSPR in this window.
Lobbying spend

JSPR lobbying filings, year to date.

Registered lobbying filings matched to Jasper Therapeutics Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for JSPR in this window.
Loading news for JSPR
Analyst ratings
Sovereign unlock shows live analyst consensus for JSPR.
Options
Sovereign unlock shows live options positioning for JSPR.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.